Phillip Securities Group
Please note that the Day Light Saving of Europe and US will be effective on April 1st and March 11th respectively. The trading hours for those relevant contracts will be 1 hour earlier. Any questions, please contact us at 22776677.For details, please visit our foreign futures website or contact us at 22776677.Moreover,the spread of USD/JPY is low as one pip.Please click here for details
  Phillip Investor Notes

24-02-2017(Fri) 23-02-2017(Thu) 22-02-2017(Wed) 21-02-2017(Tue) 20-02-2017(Mon)
Page : 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes *Advertisement*
Phillip Home Send to Friends Free Subscription Give Comments ¤¤¤åª©
24 Feb, 2017 (Friday)

Thanks to its status of the largest outsourcing service provider, Chinasoft International successfully issued 3.97% strategic shares to Huawei. Such a closer association is expected to help it obtain more outsourcing business share from Huawei, increasing from 40% in 2014 to 50% in 2015. Additionally, the Company`s JointForce Commerce Platform adopts cloud + crowd-sourcing model to achieve interconnection between related industries and to help integrate resources and boost efficiency. In the future, the Company`s revenues resulting from the platform will constantly increase with the gradual improvement in functions and efficient marketing of the platform in the future. Further, the platform`s business is characterized by high gross profit margin, which is hoped to enhance the Company`s earning capabilities. Therefore, we believe its performance will keep high growth.
Buy-in Price: $3.92, Target Price: $4.50, Cut Loss Price: $3.70

Shanghai Pharma (2607.HK) - To Benefit from the Matthew Effect Enhanced by Policy

Investment Summary

Thanks to the nationwide implementation of the "two invoices" policy, Shanghai Pharma, an industry giant, will grow faster than industry average in distribution business with endogenous and external power. The pharmacy retail layout will also become a growth point. In addition, early preparation for the quality conformance assessment for generic drugs and the possibility of several varieties entering National Drug Reimbursement List (NDRL) in 2017 are expected to boost the growth of the pharmaceutical manufacturing business. And the SOE reform is expected to form a catalyst. We give an estimation of 16x EPS in 2017 with a target price of HKD24.5, and the rating is upgraded to "Buy". (Closing price as at 22 Feb 2017)

The Matthew Effect Enhanced by Nationwide Implementation of "Two Invoices" Policy

In January 2017, National Health and Family Planning Commission officially issued the "national" two invoices policy scheme and anticipated its nationwide implementation in 2018.  So far only six provinces including Anhui and Sichuan have officially carried out the scheme. If the nationwide implementation is enabled, the concentration of distribution industry will experience a rapid increase. The three major drug-distribution enterprises take up a mere 38% market share currently, and anticipate a rise to more than 50% within three years.

Shanghai Pharma, the third largest domestic drug-distribution dealer, now has distribution network scattered across 21 provinces. It is implementing M&A strategy for a platform in each province and for expansion to 28 provinces, of which the south-western and north-eastern regions will be the focus. In Q3 2016, the company expanded business to Yunnan and Heilongjiang. We believe the "two invoices" policy and the reform of replacing the business tax with VAT will accelerate the company's M&A, and the M&A will contribute a 3 to 4 ppts increment annually for the company. In the meantime, the profitability of distribution business is also estimated to remain stable by means of adjustment in the structure of distribution products and scale intensity.

Moreover, the drug retail distribution featuring DTP takes the lead in China and anticipates optimistic prospects. Prescription drug outflow will become the biggest growth point in retail industry, and the company's various business types, professional drug stores, drug stores jointly run with hospitals and public drug stores will help handle the business. Notably, the company boasts the country's largest DTP business with a sales volume of RMB2.5 billion in 2015 (around 30% of market share), and connections with the HIS system of more than 100 hospitals, both of which constitute its edge.

Pharmaceutical Manufacturing Business May Speed Up

The company's pharmaceutical manufacturing business has been stable, but the new industry policy is expected to speed it up. First, according to the conformance assessment policy for generic drugs, the first products that pass the assessment will gain significant edge in winning contract and market. Shanghai Pharma has prepared for the policy as early as 2013, which highlights great political sensibility and forward-looking ability of the management. So far, related work of sixty or seventy varieties has started, and the overall test is projected to be completed before the end of 2018. We believe some products are estimated to complete the assessment and capture market opportunities, thereby winning greater market share.

Second, key varieties such as Live Combined Bifidobacterium Lactobacillus and Enterococcus, Polysaccharide-Iron Complex and Reinforcing Kidney Tablet have been listed on the revised drug reimbursement list of eight provinces, and are expected to enter the revised NDRL of 2017 so as to bring new opportunities to the company's growth.


The national expansion of distribution business below expectations;

The SOE reform below expectations;

Sharp rise in R&D expenses.


Click Here for PDF format...

Recommendation on 24-2-2017
Price on Recommendation Date$ 19.800
Suggested purchase priceN/A
Target Price$ 24.500
Writer Info
Fan Guohe
(Research Analyst)
Tel: (86) 21 51699400-110

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%

A-H spread
Stock Code H share
A share
H share

Oversea Research Reports

Investment Service Centre

Enquiry : 2277 6666 OR
If you cannot read this e-mail in the proper format, please click here to view the web version.

Phillip Research - Hong Kong ½÷¥ß¬ã¨s³¡ ¡V ­»´ä¤Î¤¤°ê
Company Stock Code Last Update Suggestion Target Price Price on Recom
Information Techology Research Department N/A+852 2277
O-Net Technologies87727/09/2016No Rating4.02
O-Net communications87726/10/2010BUY7.156
Transportation and Automobiles Zhang Jing (86)
Insurance Research Department (86) 21
Media & Publishing Research Department (+ 86 21 51699400-107)
Wisdom Sports Group166111/07/2016Buy3.32.18
Pharmaceutical Fan Guohe  (+ 86 21 51699400-110)
Shanghai Pharma260724/02/2017Buy24.500.000
Yibai Pharmaceutical60059417/02/2017Accumulate19.516.39
Industrial Goods Ocean Pan +852 2277
TK Group228310/01/2017Buy2.82.18
Health & Personal Care Fan Guohe  (+ 86 21 51699400-110)
Guangzhou Baiyunshan Pharma87418/10/2016Buy24.4819.16
New Energy Wang Yannan 86 21
CONCORD NE18224/10/2016Buy0.60.39
SINGYES SOLA75014/10/2016Buy5.14.12
Food, Beverage and Retail Research Department (86) 21
Ajisen (China) Holdings53823/02/2017Accumulate3.413.09
Haier Elec116921/02/2017Accumulate15.9314.4
Telecommunications Fan Guohe + (86) 21
Chinasoft International35426/10/2016Buy4.863.72
Chinasoft International35425/10/2016Buy4.863.72
Mainland Property John Wong +852 2277
Longfor Properties96009/02/2017Buy12.811.24
Kerry Properties68302/02/2017Buy26.422.05
Utilities Tim Wong +852 2277
Jiangnan Water60119920/02/2017Buy10.57.92
Properties John Wong +852 2277
Hopewell Holdings5416/02/2017Neutral27.727.5
Software & Service Research Department (86) 21
Goldpac Group331518/02/2015N/A4.77
Hotels and Entertainment John Wong (+ 852 2277 6527)
Hongkong & Shanghai Hotels4505/01/2017Accumulate9.78.46
Great Eagle Holdings Ltd4129/12/2016Accumulate38.633.65

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the ¡§Group¡¨) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products¡¦ risks, please view the Risk Disclosures Statement on

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

ª©Åv©Ò¦³¡A ½¦L¥²¨s¡C

Copyright(C) 2017 Phillip Securities (HK) Ltd. All Rights Reserved.

Copyright © 2011 Phillip Securities Group. All Rights Reserved [ Risk Disclosures Statement ] [ Terms and Conditions ] [ Personal Data Policy ]